Congenital heart defects are the most common type of birth defect. Treatment and management depends on the type and severity of the condition and can include medicines, catheter procedures, surgery and heart transplants.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
May 2025 saw several significant developments in the field of cardiology, including new regulatory approvals, long-term clinical trial data and important findings from late-breaking studies. This roundup highlights the latest updates across structural, interventional and heart failure therapies, with implications for ...
The ACT-EARLY clinical trial has dosed its first participant in an effort to prevent variant transthyretin amyloidosis (ATTRv) in genetically at-risk individuals. By evaluating the selective TTR stabilizer, acoramidis, in asymptomatic carriers, the study aims to delay or halt disease onset. With approximately 600 participants, ACT-EARLY marks a pivotal step toward shifting ATTRv care from reactive treatment to proactive prevention.
Leading experts in Pompe disease explore key data from WMS 2024 and WORLDSymposium 2025.
Novel oral therapy shows a 3.3% increase in left ventricular ejection fraction, marking a potential breakthrough in treating Duchenne muscular dystrophy cardiomyopathy In a positive development for the Duchenne muscular dystrophy (DMD) community, Cumberland Pharmaceuticals (Nashville, TN, USA) has announced positive ...
touchCARDIO is delighted to announce that Heart International has received an impressive new Impact Factor of 1.9 in the 2024 Journal Citation Reports (JCR). This achievement marks a notable increase from last year’s Impact Factor of 0.2 and highlights the journal’s growing influence in the cardiology field.
Moderate-to-severe congenital heart disease, which requires specialist cardiology care, is present in around 6/1,000 live births.1 Patients born with congenital heart defects often require surgery in early life and a consequence of this initial surgical repair is pulmonary regurgitation. The severity ...
Background: Patients with adult congenital heart disease (ACHD) are more prone to atrial arrhythmia, which increases their morbidity and mortality and risk of hospital admissions when compared with the same population where atrial arrhythmias are absent. Objective: Compare the use ...
First described in 1868 by WS Church, cor triatriatum sinister (CTS) is one of the rarest congenital heart diseases in the world, with an estimated incidence of 0.1%.1,2 It is characterised by the presence of a fibrous membrane that divides the left ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.